Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Declan G Murphy

Showing results (301-310 of 415) with videos related to

Pageof 42
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2020
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617Justin Ferdinandus, John Violet, Shahneen Sandhu, et al.
Therapeutic Advances in Medical Oncology|June 16, 2023
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature reviewDuncan E K Sutherland, Raghava Kashyap, Price Jackson, et al.
European Urology Focus|May 3, 2022
Gender Disparities Among Editorial Boards of International Urology JournalsMadeleine L Burg, Tamir Sholklapper, Priya Kohli, et al.
Pathology|January 15, 2011
Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroupMatthew K H Hong, Benjamin Namdarian, Niall M Corcoran, et al.
BJU International|March 15, 2016
Validation of the novel International Society of Urological Pathology 2014 five-tier Gleason grade grouping: biochemical recurrence rates for 3+5 disease may be overestimatedRoderick C N van den Bergh, Theo H van der Kwast, Jeroen de Jong, et al.
Trials|January 12, 2021
Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partnersPenelope Schofield, Karla Gough, Amelia Hyatt, et al.
European Urology|November 5, 2019
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysisNiranjan J Sathianathen, Samantha Koschel, Isaac A Thangasamy, et al.
BJU International|June 12, 2023
Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky?Matthew J Roberts, George Hruby, Andrew Kneebone, et al.
European Urology|January 7, 2015
Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomyGiacomo Novara, James W F Catto, Timothy Wilson, et al.
BJU International|February 12, 2017
Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trialShankar Siva, Daniel Pham, Tomas Kron, et al.
Pageof 42

Showing results (301-310 of 415) with videos related to

Sort By:
Pageof 42
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2020
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617Justin Ferdinandus, John Violet, Shahneen Sandhu, et al.
Therapeutic Advances in Medical Oncology|June 16, 2023
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature reviewDuncan E K Sutherland, Raghava Kashyap, Price Jackson, et al.
European Urology Focus|May 3, 2022
Gender Disparities Among Editorial Boards of International Urology JournalsMadeleine L Burg, Tamir Sholklapper, Priya Kohli, et al.
Pathology|January 15, 2011
Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroupMatthew K H Hong, Benjamin Namdarian, Niall M Corcoran, et al.
BJU International|March 15, 2016
Validation of the novel International Society of Urological Pathology 2014 five-tier Gleason grade grouping: biochemical recurrence rates for 3+5 disease may be overestimatedRoderick C N van den Bergh, Theo H van der Kwast, Jeroen de Jong, et al.
Trials|January 12, 2021
Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partnersPenelope Schofield, Karla Gough, Amelia Hyatt, et al.
European Urology|November 5, 2019
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysisNiranjan J Sathianathen, Samantha Koschel, Isaac A Thangasamy, et al.
BJU International|June 12, 2023
Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky?Matthew J Roberts, George Hruby, Andrew Kneebone, et al.
European Urology|January 7, 2015
Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomyGiacomo Novara, James W F Catto, Timothy Wilson, et al.
BJU International|February 12, 2017
Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trialShankar Siva, Daniel Pham, Tomas Kron, et al.
Pageof 42